Skip to content
Home » Investors

Investors

Firefly Neuroscience is Leading the Neural Revolution

View our Corporate Deck for Further Details on how BNA™ is Leading the Transformation in Healthcare Through AI

View Corporate Deck

Driving Innovation with the Firefly Neuroscience Data Platform

BNA™ Technology provides a flywheel effect that drives further growth & market offerings as the dataset grows.

  • Grows database with each new patient
  • Builds clinical insight
  • Develops capability and product opportunities
  • Drives application adoption

The commercial launch of BNA™ further drivea data growth and insight, along with topline revenue, with each additional patient.

Leveraging Big Data, Signal Processing, & AI

ROBUST COMPETITIVE ADVANTAGE

Firefly Neuroscience has the world’s largest Medical Grade Standardized database of EEG & ERP recordings to provide clinicians with technology to clearly and accurately interpret brain function.

ATTRACTIVE BUSINESS MODEL

Recurring revenue and established reimbursement. A platform built to develop future biomarkers and companion diagnostics allowing for the expansion of existing pharma collaborations and partnerships to bring new drugs to market.

INNOVATIVE TREATMENT OPPORTUNITIES

The first practical and feasible way for front-line clinicians to objectively measured and compare brain function (cognition). The Firefly Neuroscience Data Platform is an FDA-cleared (510k) & CE-marked software platform with over 7 years of clinical experience and $75M capital invested.

EXPLORE THE TECHNOLOGY

Breakthrough Innovation

Firefly Neuroscience Data Platform, powered by BNA™ technology, is the world’s largest Medical Grade standardized database with near-limitless potential growth.

Market Opportunities

Drug Therapy Development

Clinical Trials

Academic Research

Executive and Private Health Programs

Improving Patient Care Outcomes

BNA™ Potential Primary Growth Channels

Depression
1. Psychiatry

BNA™ could improve the treatment of depression significantly by objectively measuring brain health, improving and saving lives.

Learn more

Dementia
2. Neurology

BNA™ could help identify early dementia and possibly delay onset through optimized patient care.

Learn more

3. Pharma Industry

BNA™ can help objectively quantify drug impact and develop patient response models.

Learn more

Proven Utility Basis for Growth

Extensive previous experience provides tangible future development business opportunities.

Objectively measured drug impact on depression and cognition

Measured the effect of Ketamine on the brain of healthy subjects.

Objective assessment of network dynamics activated by pain.

Developed composite Memory Score for early detection of MCI & Dementia

Predicted treatment outcome with TMS

Clinical Practice: Dementia

Cognitive decline objectively measured before self-reported symptoms

Clinical Practice: Depression

Improved patient compliance to TMS therapy; objective measure on therapy impact

We Invite You To Learn More

The neural revolution is multi-layered, complex, and exciting – but it requires in-depth discussion and analysis of our go-to-market strategy, technology, and data leadership. We encourage institutional investors to book time with our leadership team for a proper investor presentation.